Risk factors for amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease. It is typically
fatal within 2–5 years of symptom onset. The incidence of ALS is largely uniform across most …
fatal within 2–5 years of symptom onset. The incidence of ALS is largely uniform across most …
Energy metabolism in ALS: an underappreciated opportunity?
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal
neurodegenerative disorder that primarily affects motor neurons. Despite our increased …
neurodegenerative disorder that primarily affects motor neurons. Despite our increased …
TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss
Microglia coordinate various functions in the central nervous system ranging from removing
synaptic connections, to maintaining brain homeostasis by monitoring neuronal function …
synaptic connections, to maintaining brain homeostasis by monitoring neuronal function …
Energy metabolism in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is characterised by the progressive degeneration of
upper and lower motor neurons. Besides motor neuron degeneration, ALS is associated …
upper and lower motor neurons. Besides motor neuron degeneration, ALS is associated …
CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder
primarily characterized by selective degeneration of both the upper motor neurons in the …
primarily characterized by selective degeneration of both the upper motor neurons in the …
Supportive and symptomatic management of amyotrophic lateral sclerosis
EV Hobson, CJ McDermott - Nature Reviews Neurology, 2016 - nature.com
The main aims in the care of individuals with amyotrophic lateral sclerosis (ALS) are to
minimize morbidity and maximize quality of life. Although no cure exists for ALS, supportive …
minimize morbidity and maximize quality of life. Although no cure exists for ALS, supportive …
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
LH Van Den Berg, E Sorenson, G Gronseth… - Neurology, 2019 - AAN Enterprises
Objective To revise the 1999 Airlie House consensus guidelines for the design and
implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral …
implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral …
Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis
Introduction: Recent studies have provided conflicting data regarding the role of
dyslipidemia in amyotrophic lateral sclerosis (ALS). The aim of this study was to determine …
dyslipidemia in amyotrophic lateral sclerosis (ALS). The aim of this study was to determine …
A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis
L Palamiuc, A Schlagowski, ST Ngo… - EMBO molecular …, 2015 - embopress.org
Amyotrophic lateral sclerosis (ALS) is the most common fatal motor neuron disease in
adults. Numerous studies indicate that ALS is a systemic disease that affects whole body …
adults. Numerous studies indicate that ALS is a systemic disease that affects whole body …
Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis
J Dorst, P Kühnlein, C Hendrich, J Kassubek… - Journal of …, 2011 - Springer
Weight loss is a common phenomenon and an independent prognostic factor in amyotrophic
lateral sclerosis (ALS). Several potential causal mechanisms, including intrinsic …
lateral sclerosis (ALS). Several potential causal mechanisms, including intrinsic …